Over 80% of Americans would buy generic Rx drug more often than branded product

17 March 2015
usa-white-house

Americans favor generic prescription drugs over brand name products by a considerable margin, according to new research. Some 81% of those who buy prescription drugs say they would purchase generics more often than brand name drugs.

A new Harris Poll finds that a 42% subset goes so far as to assert that they would "always" choose to buy a generic drug. Older generations are especially likely to indicate that they would always go with generics (50% Matures, 44% Baby Boomers, and 46% Gen X versus 33% Millennials).

Meanwhile, this means that only 19% of those who purchase prescription drugs would more often choose to fill their script with the brand name drug, and a mere 6% would "always" choose brand names. It is worth noting, however, that though majorities of adults both with and without children in their households favor generics, the minority preference for brand names is stronger among those with children in the household (24% with vs. 17% without).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics